Login to Your Account

Demand by FDA 'low bar,' Steadymed advancing PAH drug/device

By Randy Osborne
Staff Writer

Friday, December 8, 2017

Steadymed Ltd. CEO Jonathan Rigby told BioWorld that officials at his firm "feel more confident now than we ever have that we know exactly what the agency wants to see," after the FDA provided guidance regarding what's needed to resubmit the NDA for Trevyent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription